Value-based payment models, largely based on the Triple Aim framework, require health systems and physician organizations to consistently generate value by improving patient outcomes while reducing per capita costs.
Population health, typically a focused investment of incremental resources on high cost patients, is a central component of value-based care and an area where many health systems and physician organizations have made a significant investment. However, despite the noble ambitions of population health investments, the ability to consistently generate value varies greatly from one organization to the next. Why is this?
Based on our experiences of working with nearly 100 provider-led organizations along a broad spectrum of value-based risk contracts, one of the key determinants of an organization’s ability to generate value is their ability to appropriately identify, engage and intervene with “impactable” patients.
While not a word you can find in a dictionary (yet), the concept of impactability is essential to driving a return on your population health investments. This webinar will describe key impactability concepts we have developed across our work, walk through a case example and briefly touch on how to put these concepts into practice.
About the Author
As Evolent Health’s Senior Vice President of Research and Development, Anita leads the teams responsible for advanced analytics, clinical program design, and evaluation of clinical initiatives. Anita holds a PhD in Clinical Epidemiology from Harvard University and has spent that last 10 years building risk models and evaluating the impact of clinical programs for the National Institutes of Health, the Department of Defense, the Centers for Disease Control, and USAID. Prior to joining Evolent, Anita served as a Senior Associate at Booz Allen Hamilton building the firm’s Evaluation Practice and prior to that was the Director of Monitoring and Evaluation for Partners in Health, Rwanda. Anita received a BS in Biomedical Engineering from Northwestern University and a MS in Biomedical Engineering from Harvard University.More Content by Anita Cattrell